# CHERISH Study: Later-Onset SMA Treatment Outcomes
Keywords: SMA, 5q SMA, CHERISH study, nusinersen, motor milestones, WHO motor milestones, Type II SMA, HFMSE, RULM, adverse events

> This page provides an overview of the CHERISH study, a clinical trial evaluating the effectiveness of nusinersen in treating later-onset spinal muscular atrophy (SMA), with a focus on motor milestone achievements and safety outcomes.

## Details
- [CHERISH Study Overview](#): A Phase III, multicenter, randomized study assessing nusinersen in children with later-onset SMA, focusing on motor function improvements and safety.
- [Motor Milestones](#): Highlights the proportion of patients achieving new WHO motor milestones after 15 months of treatment with nusinersen compared to a sham control.
- [Study Description](#): Detailed methodology of the CHERISH study, including patient demographics, treatment duration, and primary and secondary endpoints.
- [WHO Motor Milestones](#): Description of six major motor milestones expected in healthy children by 24 months, used as a benchmark in the study.
- [Adverse Event Reporting](#): Instructions for reporting adverse events in the UK and Ireland, including contact details for Biogen and regulatory authorities.